{"count": 5, "results": [{"_id": "28516068", "pmid": 28516068, "pmcid": "PMC5385703", "title": "A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients", "journal": "Adv Biomed Res", "authors": ["Iraji F", "Banihashemi SH", "Faghihi G", "Shahmoradi Z", "Tajmirriahi N", "Jazi SB"], "date": "2017-03-28T00:00:00Z", "doi": "10.4103/2277-9175.203159", "meta_date_publication": "2017", "meta_volume": "6", "meta_issue": "", "meta_pages": "34", "score": 50072.62, "text_hl": "Corticosteroids are known to be effective, but with modest results. Although @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ has been reported to be effective for immunorelated @<m>DISEASE_Acrocephalosyndactylia</m> @DISEASE_MESH:D000168 @@@dermatologic disorders@@@ including @DISEASE_Vitiligo @DISEASE_MESH:D014820 @@@vitiligo@@@, controlled trials are lacking. ", "citations": {"NLM": "Iraji F, Banihashemi SH, Faghihi G, Shahmoradi Z, Tajmirriahi N, Jazi SB. A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients Adv Biomed Res. 2017;6():34. PMID: 28516068", "BibTeX": "@article{28516068, title={A Comparison of Betamethasone Valerate 0.1% Cream Twice Daily Plus Oral Simvastatin Versus Betamethasone Valerate 0.1% Cream Alone in the Treatment of Vitiligo Patients}, author={Iraji F and Banihashemi SH and Faghihi G and Shahmoradi Z and Tajmirriahi N and Jazi SB}, journal={Adv Biomed Res}, volume={6}, pages={34}}"}}, {"_id": "21558878", "pmid": 21558878, "title": "Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events.", "journal": "J Cardiovasc Pharmacol", "authors": ["Undas A", "Machnik A", "Potaczek DP", "Wypasek E", "Zmudka K", "Tracz W"], "date": "2011-08-01T00:00:00Z", "doi": "10.1097/FJC.0b013e31821e8cb2", "meta_date_publication": "2011 Aug", "meta_volume": "58", "meta_issue": "2", "meta_pages": "167-72", "score": 50070.395, "text_hl": "In an investigator-initiated, double-blind, placebo-controlled, randomized study, @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Acrocephalosyndactylia</m> @DISEASE_MESH:D000168 @@@ACS@@@ were assigned to 40 mg/d of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ + 10 mg/d of @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@ (n = 26) or 40 mg/d of @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ + placebo (n = 28) administered for 2 months. ", "citations": {"NLM": "Undas A, Machnik A, Potaczek DP, Wypasek E, Zmudka K, Tracz W. Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events. J Cardiovasc Pharmacol. 2011 Aug;58(2):167-72. PMID: 21558878", "BibTeX": "@article{21558878, title={Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events.}, author={Undas A and Machnik A and Potaczek DP and Wypasek E and Zmudka K and Tracz W}, journal={J Cardiovasc Pharmacol}, volume={58}, number={2}, pages={167-72}}"}}, {"_id": "19061694", "pmid": 19061694, "title": "Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.", "journal": "Am Heart J", "authors": ["Cannon CP", "Giugliano RP", "Blazing MA", "Harrington RA", "Peterson JL", "Sisk CM", "Strony J", "Musliner TA", "McCabe CH", "Veltri E", "Braunwald E", "Califf RM", "IMPROVE-IT Investigators"], "date": "2008-11-01T00:00:00Z", "doi": "10.1016/j.ahj.2008.07.023", "meta_date_publication": "2008 Nov", "meta_volume": "156", "meta_issue": "5", "meta_pages": "826-32", "score": 50065.88, "text_hl": "STUDY DESIGN: The study will recruit up to 18,000 moderate- to high-risk @SPECIES_9606 @@@patients@@@ stabilized after @<m>DISEASE_Acrocephalosyndactylia</m> @DISEASE_MESH:D000168 @@@ACS@@@. @SPECIES_9606 @@@Patients@@@ are randomized in a 1:1 ratio to once-daily doses of either @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@/@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ 10/40 mg or @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ monotherapy 40 mg. ", "citations": {"NLM": "Cannon CP, Giugliano RP, Blazing MA, Harrington RA, Peterson JL, Sisk CM, Strony J, Musliner TA, McCabe CH, Veltri E, Braunwald E, Califf RM, IMPROVE-IT Investigators. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008 Nov;156(5):826-32. PMID: 19061694", "BibTeX": "@article{19061694, title={Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes.}, author={Cannon CP and Giugliano RP and Blazing MA and Harrington RA and Peterson JL and Sisk CM and Strony J and Musliner TA and McCabe CH and Veltri E and Braunwald E and Califf RM and IMPROVE-IT Investigators}, journal={Am Heart J}, volume={156}, number={5}, pages={826-32}}"}}, {"_id": "28716519", "pmid": 28716519, "title": "Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial.", "journal": "Heart Lung Circ", "authors": ["Almalki ZS", "Guo JJ", "Alahmari A", "Alotaibi N", "Thaibah H"], "date": "2018-06-01T00:00:00Z", "doi": "10.1016/j.hlc.2017.05.139", "meta_date_publication": "2018 Jun", "meta_volume": "27", "meta_issue": "6", "meta_pages": "656-665", "score": 50057.566, "text_hl": "The aim of this study is to investigate the cost-effectiveness of adding @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@ to @<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ treatment for @SPECIES_9606 @@@patients@@@ with @<m>DISEASE_Acrocephalosyndactylia</m> @DISEASE_MESH:D000168 @@@ACS@@@ based on the recently completed IMPROVE-IT trial. ", "citations": {"NLM": "Almalki ZS, Guo JJ, Alahmari A, Alotaibi N, Thaibah H. Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial. Heart Lung Circ. 2018 Jun;27(6):656-665. PMID: 28716519", "BibTeX": "@article{28716519, title={Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial.}, author={Almalki ZS and Guo JJ and Alahmari A and Alotaibi N and Thaibah H}, journal={Heart Lung Circ}, volume={27}, number={6}, pages={656-665}}"}}, {"_id": "29903515", "pmid": 29903515, "title": "The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.", "journal": "Int J Cardiol", "authors": ["Simon TG", "Corey KE", "Cannon CP", "Blazing M", "Park JG", "O'Donoghue ML", "Chung RT", "Giugliano RP"], "date": "2018-11-01T00:00:00Z", "doi": "10.1016/j.ijcard.2018.05.087", "meta_date_publication": "2018 Nov 1", "meta_volume": "270", "meta_issue": "", "meta_pages": "245-252", "score": 50046.914, "text_hl": "METHODS: We applied the NFS prospectively to 14,819 @<m>DISEASE_Acrocephalosyndactylia</m> @DISEASE_MESH:D000168 @@@post-ACS@@@ @SPECIES_9606 @@@patients@@@ randomized to @CHEMICAL_Ezetimibe @CHEMICAL_MESH:D000069438 @@@ezetimibe@@@/@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ (E/S) or placebo/@<m>CHEMICAL_Simvastatin</m> @CHEMICAL_MESH:D019821 @@@simvastatin@@@ (P/S), in the IMPROVE-IT trial, using validated NFS cutoffs. ", "citations": {"NLM": "Simon TG, Corey KE, Cannon CP, Blazing M, Park JG, O'Donoghue ML, Chung RT, Giugliano RP. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe. Int J Cardiol. 2018 Nov 1;270():245-252. PMID: 29903515", "BibTeX": "@article{29903515, title={The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe.}, author={Simon TG and Corey KE and Cannon CP and Blazing M and Park JG and O'Donoghue ML and Chung RT and Giugliano RP}, journal={Int J Cardiol}, volume={270}, pages={245-252}}"}}]}